9999999997-15-007418.txt : 20150403 9999999997-15-007418.hdr.sgml : 20150403 20150403113032 ACCESSION NUMBER: 9999999997-15-007418 CONFORMED SUBMISSION TYPE: CT ORDER PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20150403 DATE AS OF CHANGE: 20150403 20150403 20150403 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Vascular Biogenics Ltd. CENTRAL INDEX KEY: 0001603207 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: L3 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: CT ORDER SEC ACT: 1934 Act SEC FILE NUMBER: 001-36581 FILM NUMBER: 15750531 BUSINESS ADDRESS: STREET 1: 6 JONATHAN NETANYAHU ST. CITY: OR YEHUDA STATE: L3 ZIP: 60376 BUSINESS PHONE: 972-3-6346450 MAIL ADDRESS: STREET 1: 6 JONATHAN NETANYAHU ST. CITY: OR YEHUDA STATE: L3 ZIP: 60376 CT ORDER 1 filename1.pdf begin 644 filename1.pdf M)5!$1BTQ+C4-"B6UM;6U#0HQ(#`@;V)J#0H\/"]4>7!E+T-A=&%L;V7!E+U!A9V5S+T-O=6YT(#$O2VED'0O26UA9V5"+TEM86=E0R]);6%G M94E=(#X^+TUE9&EA0F]X6R`P(#`@-C$R(#2]#4R]$979I8V52 M1T(^/B]486)S+U,O4W1R=6-T4&%R96YT)RE66UOVS@,_EZ@_T'`?;&!1;,D6[8/PX`V3;L.:WMHLV'`=CBDC=,8 M2.PN<6[;OS^2CI,HMEP!MP%I7AX]HDCJ(26SMW^Q=^_>W@RO+UCP_CT[OQBR M\_'IR=M+P81DX]GIB6`!_!=,1@D7,8N#A*'HR@DEPHH9=18JGT2'[ M-X\=8-GH9LC8@;7BP-J&1,2:QPG3:<1%0_*PLV3X&2R[OQY?XP?ZAGYC9VCQ M!1M]]87PAA_HXY6?U!`VO+OQ!Y%W@ZMZP(70H.N[6\M"0A5Q*4T;>AWX^A8=S?Q!Z@WO;B]]`9Z]&-V.T?/7 M9Y\89=9D.B0X^!%?N,I&2&HT??]BE M$WL]LVQ1@B1/E#D#C?HZ!!Y(P"L?UEM/8J.`"&.,#BG.<#2YCMU=@I.92%5H M=93BPAS>ZR?=DR=2.V9ZW)7I8_4?A(ZNWI)3%OE9H24DNO(Q'["++2KEP1QE,*1'L11 M'9FRWCPN41]SJZA`:AV-J:I&CJ;6J:"C.AXV041(\03O\7-%G\J" M;8HITJ[8O:T4!K"54I-WL\A@:8^V$9#14ILC;+(10GV31TE@VWK8O1QC;=[` M`GZ,7?D#33[\L<'7-?A40!B*9^JQNGF:A(;R&3<\Z,.RF.7@N,@K:D^B3Q>, MHK3*(%W)Q\LF:$7%*'MGY8H:G[S`=Z&WG%0YQ(`8*I;]0@U$]L5FFDW9#.A7 MY9)5\XR-X-M?UF8G0>,,&^?Y8\UJVR2AB$C;#P=9G2D2KE(36Y5LPB[!8%#/X_7`A6+8I>%@PSIX,['U*NLI?-X[Y=6E`$?OLJ\-@T7S\MRC5]0W/G-((S M=%(MR12E:5[L]Q(02"20`;@FHT(.!N_K/"[FJ".8X7LL_<@^IYDH`Q9H#/S] MB5T+4+^V/CC>[C1P-_.N-[#*&31-YEB(L@T;\U";8)MH""7Q)L0D]GLJF#"Q M?07L"/HS7U`A9AC4QXSA5LEL0@F%`AIG8_PBHX-(G4/0ZAS$P<@-MMN7NYRO MTWJ9L9<,MV1>3GO:-AD[^EG!*5\J-S\KT)U4./HY#`*>Q&Z.#@/5PJY?LB>L M'75_2SHY_;.G@>^9JEV8NZX?F]2&0UYG?6BS=%W.-2Q!Y'Q0=<-JZ8Y-$SSY M&]C1+ZPKM$,U'`E".-+;TA9/ZLIM)AD'K9GLMZ]TKV9@J_FJW#SCL7ANOP;4 ME,V'PS[2Q30=0JF80GT2NA9"F`;;1OM10"9XO^)D,::5<(0FVA6ZS1"5BM=/ M#=L,<#;QIFE&, M5T4;O)9`E[*^K]5/S8GH#6CG:KU!92UVI?85[VO8`8W-=%&QR%!DJ?C1;-OZ MB>\WU;QFY`\3G+\Y)Y83=IKP3MA9%)ZQ4H3NVED`G[%8"#2P>D.CT!JG[<=O^ M4H9GBZFU$,<1CU/[G.VH=-VI;JW!^[U=MCXT>PJ;$#*KFN`V:!36=FH3>(-N M,/7;TW.^EO@0U8VEYWPM\2FJ&TM/,R#Q@:8;2T\S(/%QGY7E/W7!E+T9O;G0O4W5B='EP M92]4'1'4W1A=&4O0DTO3F]R;6%L+V-A(#$^/@T*96YD;V)J#0HX(#`@ M;V)J#0H\/"]4>7!E+T9O;G0O4W5B='EP92]4%=I9'1H(#(U M-C@O1F]N=%=E:6=H="`T,#`O6$AE:6=H="`R-3`O3&5A9&EN9R`T,B]3=&5M M5B`T,"]&;VYT0D)O>%L@+34V."`M,C$V(#(P,#`@-CDS72`^/@T*96YD;V)J M#0HQ,"`P(&]B:@T*/#PO075T:&]R*&AA7!E+T]B:E-T;2].(#,R+T9I.)82T6D`@1%6UE?:`.(36VT:T,0JI!&^_XTP1.7`@ONW%8X_G M_V+'?^-B"05@!24">L!"@^9Q2:"1>P8T)\H2-`$5%K0!*AUGP!05:`NF]*`= MJPO0#+%<[<$BEQ5@K05"<$PG#!I'AB.GAN>MXQ#3CED&,][W@=RRCL+%Q=J MGHH+6*BEFJO5QVM0R[X[KOOK?3BH^T*F2ZKI$I]QE#G'GW'^F&$`S'``9E@`,SR`&2;`#!=@A@TPPP62P7I"AJ"'P+?04-`"5H"23`2 M1,=?_"$X"4+10B&AD%!(*"04$@H)A81"0B&AD%",4(Q0C%#,0'F"TSY'^UIU M(2QB[-4B[L-#_9HNI/0&>/^A'6;3U90RPV]4,*/967CO[\,'X`E]PZPV]D'- M4G/=;KX&*RY]CN]J&=:]N@WU)G323YK/_EV[;]JPW-5IA2GQJV5"W3>Q/8V[ MOOE;=N%T,L1/M3K+H[&OW?7!E M+UA2968O4VEZ92`T-B]76R`Q(#0@,ET@+U)O;W0@,2`P(%(O26YF;R`Q,"`P M(%(O241;/$8R-C!%03)"-T5#-D%#-#DY04)#,SA&140S03,U.#,Y/CQ&,C8P M14$R0C=%0S9!0S0Y.4%"0S,X1D5$,T$S-3@S.3Y=("]&:6QT97(O1FQA=&5$ M96-O9&4O3&5N9W1H(#$S,CX^#0IS=')E86T-"GB<-<_)$8)0#(#A/,2%51Z; MNQ1B+]9@`[9@`];!S9NTPH$JX)%?<\@WF4DRB8B+<30N6Y&9)[2*^2C!H(1O M)7K!5XD?2G(7\73+&2YPA1/\6AHWD-[^E0$/%N##$E:PA@T$$$($,220PA8R ML)!#`2544,,.]G"`HSL^Z_1IVXM,/T\.5`T*96YDF4@ M-#